Gross margin has clearly repaired itself, climbing from the 12.2% trough in 2024Q4 to 22.6% in 2026Q4, which suggests the pricing and mix environment has normalized versus a year ago. However, the operating line has given back that gain as SG&A grew roughly 85% against 63% revenue growth, so the marginal revenue being added appears carrying below-average incremental profitability. With operating income of $3.7M more than erased by approximately $10.8M of non-operating charges, net margin rather than gross margin is arguably the more honest read of current earning power, and it is negative in the latest quarter.

The ROIC trend does not yet show compounding; the peak of 2.9% in 2025Q4 has faded to 1.2% even as the asset base expanded 79% sequentially in 2026Q4, implying the newly acquired assets are not yet contributing measurable returns. ROE has been more erratic than ROIC, swinging from -4.2% to +3.1% across the window, which points to net-income volatility — not leverage or efficiency — as the dominant driver of equity returns. Because roughly $105.6M of the asset base is newly recognized goodwill that will be included in invested capital going forward, ROIC may face mechanical downward pressure unless the acquired operation delivers earnings quickly; this warrants monitoring against reported segment results.

DSO of 9 days indicates receivables are effectively a non-issue, so virtually all of the working capital question sits with inventory, where 54 days of stock still represents the bulk of the cycle for a builder of high-ticket boats. The compression from 62 to 42 days has provided a genuine, if partly non-recurring, cash tailwind — consistent with the $4.4M working capital release that let 2026Q4 operating cash flow of $17.0M coexist with a $7.1M net loss. Investors should note that asset turnover improved to 0.33 from 0.20 over the period, but the denominator was restated upward by the acquisition, so part of that efficiency gain appears to be accounting-driven rather than purely operational.

With D/E disclosed at only 0.26-0.28 through 2025Q1 and unavailable thereafter, and zero interest-bearing debt reported in 2026Q4, refinancing or covenant risk appears minimal on the face of the balance sheet — a meaningful buffer relative to peers such as ONEW at 3.38x and HZO at 1.31x D/E. The extreme volatility in the coverage ratio, including a negative reading in 2026Q3 and a 4548x print in 2026Q1, implies the denominator is close to zero and occasionally negative, which makes it analytically unusable as a solvency test. The more relevant leverage question may therefore be prospective rather than contractual: $54.1M of acquisition spending in 2026Q4 was funded without disclosed new borrowing, and whether that posture is maintained warrants scrutiny of subsequent filings.

The 4x gap between trailing and forward P/E suggests the market is underwriting a recovery in earnings that the last four quarters have not yet demonstrated, given net margin of -5.5% in 2026Q4 versus +7.2% in 2025Q4. Against the peer set, MCFT's 13.88x EV/EBITDA sits above MBUU (6.92x) and HZO (14.64x is comparable) but well below BC (25.5x), while its 1.76x P/B is high relative to MBUU at 0.83x and HZO at 1.22x — a premium that appears to rest heavily on the acquired goodwill now at 27% of assets. P/S of 1.12x and P/FCF of 12.04x look more reasonable in isolation, but the FCF multiple benefits from the working capital release and capex running below depreciation, so normalized cash earnings could be lower than the headline implies.